PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2

BACKGROUND: Predict (www.predict.nhs.uk) is an online, breast cancer prognostication and treatment benefit tool. The aim of this study was to incorporate the prognostic effect of HER2 status in a new version (Predict+), and to compare its performance with the original Predict and Adjuvant!. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Wishart, G C, Bajdik, C D, Dicks, E, Provenzano, E, Schmidt, M K, Sherman, M, Greenberg, D C, Green, A R, Gelmon, K A, Kosma, V-M, Olson, J E, Beckmann, M W, Winqvist, R, Cross, S S, Severi, G, Huntsman, D, Pylkäs, K, Ellis, I, Nielsen, T O, Giles, G, Blomqvist, C, Fasching, P A, Couch, F J, Rakha, E, Foulkes, W D, Blows, F M, Bégin, L R, van't Veer, L J, Southey, M, Nevanlinna, H, Mannermaa, A, Cox, A, Cheang, M, Baglietto, L, Caldas, C, Garcia-Closas, M, Pharoah, P D P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425970/
https://www.ncbi.nlm.nih.gov/pubmed/22850554
http://dx.doi.org/10.1038/bjc.2012.338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425970/
https://www.ncbi.nlm.nih.gov/pubmed/22850554
http://dx.doi.org/10.1038/bjc.2012.338

Ejemplares similares